Literature DB >> 1261164

Disposition of propoxyphene and propranolol in children.

J T Wilson, G F Atwood, D G Shand.   

Abstract

The disposition of propoxyphene and propranolol was studied in children by means of two protocols which minimized the number of blood samples taken from each child. Propoxyphene and its metabolite, norpropoxyphene, were measured in two plasma samples obtained from different children at various times after a single oral dose. These data were pooled and a plasma concentration/time curve was obtained which was consistent with an average T 1/2 of 3.5 hr in this population. The bioavailability of tablets and a solution of propranolol was compared with a crossover design by obtaining plasma samples at the end of the dosage interval during chronic oral administration of various doses. No clear differences in the bioavailability of the two formulations could be detected. Both drugs showed marked interindividual differences in plasma concentrations following oral administration. These findings are consistent with the high hepatic extraction ratio and large presystemic (first pass) effect previously described in adults. The large individual variability supports the concept of monitoring plasma levels as an aid to therapy and demonstrates that the use of a weight-adjusted dose in children can be only an approximation for initial treatment.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1261164     DOI: 10.1002/cpt1976193264

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  Influence of age on serum protein binding of propranolol.

Authors:  R Bendayan; J A Pieper; R B Stewart; G J Caranasos
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

2.  Clinical pharmacokinetics in infants and children.

Authors:  A Rane; J T Wilson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.

Authors:  G Johnsson; C G Regàrdh
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 4.  Paediatric labelling requirements. Implications for pharmacokinetic studies.

Authors:  J T Wilson; G L Kearns; D Murphy; S J Yaffe
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

5.  Oxandrolone Coadministration Does Not Alter Plasma Propranolol Concentrations in Severely Burned Pediatric Patients.

Authors:  Ashley N Guillory; David N Herndon; Michael B Silva; Clark R Andersen; Oscar E Suman; Celeste C Finnerty
Journal:  J Burn Care Res       Date:  2017 Jul/Aug       Impact factor: 1.845

6.  Propranolol pharmacokinetics in infants treated for Infantile Hemangiomas requiring systemic therapy: Modeling and dosing regimen recommendations.

Authors:  Laurence Del Frari; Christine Léauté-Labrèze; Laurent Guibaud; Sébastien Barbarot; Jean-Philippe Lacour; Christine Chaumont; Alain Delarue; Jean-Jacques Voisard; Valérie Brunner
Journal:  Pharmacol Res Perspect       Date:  2018-04-30

7.  Population Pharmacokinetics and Pharmacodynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma.

Authors:  Tomoki Takechi; Tadao Kumokawa; Rumiko Kato; Takeshi Higuchi; Tsuyoshi Kaneko; Ichiro Ieiri
Journal:  J Clin Pharmacol       Date:  2018-05-10       Impact factor: 3.126

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.